Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26367195
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Future+Oncol
2015 ; 11
(20
): 2819-30
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
A comprehensive review of pacritinib in myelofibrosis
#MMPMID26367195
Verstovsek S
; Komrokji RS
Future Oncol
2015[]; 11
(20
): 2819-30
PMID26367195
show ga
The first-in-class JAK1/JAK2 inhibitor ruxolitinib inhibits JAK/STAT signaling,
inducing durable reductions in splenomegaly and constitutional symptoms in
patients with myelofibrosis. However, the association of ruxolitinib therapy with
myelosuppression indicates the continued need for optimal treatment choices in
myelofibrosis. Pacritinib, a dual JAK2 and FLT3 inhibitor, improves
disease-related symptoms and signs with manageable gastrointestinal toxicity in
patients with myelofibrosis with splenomegaly and high-risk features, without
causing overt myelosuppression, and therefore may provide an important treatment
option for a range of patients with myelofibrosis. This article examines the role
of JAK2 and FLT3 signaling in myelofibrosis and provides an overview of the
clinical development of pacritinib as a new therapy for myelofibrosis.
|Bridged-Ring Compounds/*therapeutic use
[MESH]
|Humans
[MESH]
|Janus Kinase 2/*antagonists & inhibitors
[MESH]
|Primary Myelofibrosis/*drug therapy
[MESH]
|Protein Kinase Inhibitors/*therapeutic use
[MESH]
free
free
free
